Download MendeleyStructure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity.
Vasas, A., Ivanschitz, L., Molnar, B., Kiss, A., Baker, L., Fiumana, A., Macias, A., Murray, J.B., Sanders, E., Whitehead, N., Hubbard, R.E., Saunier, C., Monceau, E., Girard, A.M., Rousseau, M., Chanrion, M., Demarles, D., Geneste, O., Weber, C., Lewkowicz, E., Kotschy, A.(2024) J Med Chem
- PubMed: 39441669
- DOI: https://doi.org/10.1021/acs.jmedchem.4c01472
- Primary Citation of Related Structures:
9FIO, 9FIP, 9FIQ, 9FIR, 9FIS, 9FIT, 9FIU, 9FIV - PubMed Abstract:
Inhibition of ubiquitin-specific protease 7, USP7, has been proposed as a mechanism to affect many disease processes, primarily those implicated in oncology. The bound crystal structure of a published high-throughput screening hit with low-micromolar affinity for USP7 identified three regions of the compound for structure-guided optimization. Replacing one side of the compound with different aromatic moieties gave little improvement in affinity, and the central piperidine could not be improved. However, the binding site for the other side of the compound was poorly defined in the crystal structure, which suggested a wide variety of synthetically accessible options for optimization. These were assessed by screening reaction mixtures that introduced different substituents to this other side. Subsequent optimization led to a compound with low-nanomolar affinity for USP7, which showed target engagement in tumors, was tolerated in mice, and showed efficacy in xenograft models.
Organizational Affiliation:
Servier Research Institute of Medicinal Chemistry, Záhony u. 7., Budapest H-1031, Hungary.
